BACKGROUND: IPMN is a precursor lesion to pancreatic ductal adenocarcinoma consisting of 4 epithelial subtypes with varying grades of dysplasia. Intestinal type (IPMN-I) often involves the main duct and has a higher risk of developing invasive carcinoma in comparison to gastric type (IPMN-G). Differentiation of high-risk/malignant IPMN from low-risk IPMN and other benign/low-grade cystic pancreatic lesions remains a challenge, especially in the preoperative setting. mAb Das-1 reacts specifically to a colonic epithelial phenotype. It is both sensitive and specific in identifying various pre-malignant and malignant lesions of the upper GI tract including Barrett's esophagus and incomplete gastrointestinal metaplasia associated with gastric cancer. We have previously demonstrated that it specifically detects high risk IPMN tissue histologically. AIM: To assess the ability of mAb Das-1 to identify cyst fluid of IPMN with a high risk of malignant transformation. METHODS: Cyst fluid was aspirated during surgical resection of IPMN (n=10), serous cystadenoma (n=1), and cystic low-grade neuroendocrine tumor (n=1). Cyst fluid was also aspirated during EUS-FNA of pancreatic pseudocysts (n=4). Sandwich ELISA was performed on each sample (utilizing mAb Das-1 IgM & IgG isotypes) and results were confirmed by Western Blot analysis. Statistical significance was calculated by T-test. RESULTS: Pancreatic cyst fluid from all benign/low-grade lesions (n=8) demonstrated very little reactivity with mAb Das-1 (OD 0.137±0.181). Specifically, reactivity was low among cyst fluid collected from low-grade IPMN-G (OD 0.088±0.003, n=2), pseudocyst (n=4) (OD 0.088±0.041), and non-pseudocyst, benign/low-grade lesions (n=4) (OD 0.187±0.251). In comparison, high-risk and malignant IPMN lesions (intermediate-grade IPMN-I & all high-grade/invasive IPMNs n=8) expressed a significantly higher amount of reactivity (OD 0.866±0.151) when compared to low-grade IPMN-G (p<0.001), pseudocyst (p<0.001), and all benign/low-grade lesions (p<0.002). When stratified by subtype, low-grade IPMN-G (n=2, OD 0.088±0.003), IPMN-G with highgrade dysplasia or invasive carcinoma (n=2, OD 0.402±0.313), intermediate-grade IPMN-I (n=2, OD 0.6339±0.100), IPMN-I with high-grade dysplasia or invasive carcinoma (n=3, OD 1.232±0.265) and high-grade Oncocytic IPMN (OD 1.161), demonstrated a progressive increase in reactivity to mAb Das-1 among each subtype. All results obtained by ELISA were confirmed by western blot analysis. CONCLUSION: mAb Das-1 demonstrates significantly higher reactivity in cyst fluid from high-risk and malignant IPMN compared to fluid from low-grade IPMN-G, pancreatic pseudocyts, and other low-grade pancreatic cystic lesions. The expression of this marker in preoperative cyst fluid may be a useful tool to identify high-risk IPMN lesions and stratify surgical management.
Read full abstract